Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants.

Antiviral research - 1 Jul 2026

Chiba Shiho, Kiso Maki, Yamayoshi Seiya, Uraki Ryuta, Kawaoka Yoshihiro

Abstract excerpt

The recurrent spillover of highly pathogenic avian influenza (HPAI) H5 viruses into humans represents a major public health concern that is exacerbated by the emergence of drug-resistant viral variants. Host-targeting antiviral approaches, including drug repurposing, offer a promising alternative to conventional virus-directed therapeutics. Here, we evaluated the antiviral activity of niclosamide, an FDA-approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Dogs
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Influenza A Virus, H5N1 Subtype

Share to Influenza in Birds

Share to Inhibitory Concentration 50

Share to Madin Darby Canine Kidney Cells

Share to Triazines

Source

Identifiers

PMID: 42070632
DOI: 10.1016/j.antiviral.2026.106421

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants.PMID 42070632Read ↗

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variantSemantic proximity Read ↗

A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last DecadeSemantic proximity Read ↗

Host-directed antiviral therapeutics and the NIAID research agenda: an underexplored frontierSemantic proximity Read ↗

Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cellsSemantic proximity Read ↗

In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 TreatmentSemantic proximity Read ↗

Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivoSemantic proximity Read ↗

Characterization of the in Vitro and in Vivo Efficacy of Baloxavir Marboxil against h5 Highly Pathogenic Avian Influenza Virus InfectionSemantic proximity Read ↗

Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses.Semantic proximity Read ↗

Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication<i>In Vitro</i>and<i>In Vivo</i>Semantic proximity Read ↗

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxilSemantic proximity Read ↗

A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants.Semantic proximity Read ↗

In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.